Company profile
ADC Therapeutics S.A.
Pipeline1 asset
- loncastuximab tesirine-lpylZYNLONTA / CD19 / antibody-drug conjugate / OncologyLOTIS-2 in 3L+ r/r DLBCLPhase 3/ConfirmatoryLOTIS-5 in r/r DLBCLPhase 3/ConfirmatoryLOTIS-7 in r/r B-NHLPhase 1b
Latest news9 items
All newsADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial
Enrollment • Phase 1Enrollment milestone Tue, Jun 30, 2026
ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Trial Results • Phase 3Topline results Wed, Jun 3, 2026